- Home
- KZIA vs NEUP Comparison
KZIA vs NEUP Comparison
Compare KZIA & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- NEUP
- Stock Information
- Founded
- KZIA 1994
- NEUP 1996
- Country
- KZIA Australia
- NEUP United States
- Employees
- KZIA N/A
- NEUP N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- NEUP
- Sector
- KZIA Health Care
- NEUP
- Exchange
- KZIA Nasdaq
- NEUP Nasdaq
- Market Cap
- KZIA 11.7M
- NEUP 12.7M
- IPO Year
- KZIA 1999
- NEUP N/A
- Fundamental
- Price
- KZIA $8.68
- NEUP $7.59
- Analyst Decision
- KZIA Strong Buy
- NEUP Strong Buy
- Analyst Count
- KZIA 2
- NEUP 1
- Target Price
- KZIA $14.00
- NEUP $21.00
- AVG Volume (30 Days)
- KZIA 675.5K
- NEUP 42.2K
- Earning Date
- KZIA 08-12-2025
- NEUP 08-15-2025
- Dividend Yield
- KZIA N/A
- NEUP N/A
- EPS Growth
- KZIA N/A
- NEUP N/A
- EPS
- KZIA N/A
- NEUP 0.00
- Revenue
- KZIA $1,549,158.00
- NEUP $15,662,715.00
- Revenue This Year
- KZIA N/A
- NEUP N/A
- Revenue Next Year
- KZIA $49.25
- NEUP N/A
- P/E Ratio
- KZIA N/A
- NEUP $4,502.65
- Revenue Growth
- KZIA 248983.08
- NEUP N/A
- 52 Week Low
- KZIA $2.86
- NEUP $2.90
- 52 Week High
- KZIA $39.05
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- KZIA 50.61
- NEUP N/A
- Support Level
- KZIA $7.40
- NEUP N/A
- Resistance Level
- KZIA $10.08
- NEUP N/A
- Average True Range (ATR)
- KZIA 0.78
- NEUP 0.00
- MACD
- KZIA -0.29
- NEUP 0.00
- Stochastic Oscillator
- KZIA 42.38
- NEUP 0.00
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.